ATE194494T1 - Kombinierte zelluläre und immunsuppressive therapien - Google Patents

Kombinierte zelluläre und immunsuppressive therapien

Info

Publication number
ATE194494T1
ATE194494T1 AT92922624T AT92922624T ATE194494T1 AT E194494 T1 ATE194494 T1 AT E194494T1 AT 92922624 T AT92922624 T AT 92922624T AT 92922624 T AT92922624 T AT 92922624T AT E194494 T1 ATE194494 T1 AT E194494T1
Authority
AT
Austria
Prior art keywords
cells
immunosupressive
therapies
foreign
combined cellular
Prior art date
Application number
AT92922624T
Other languages
English (en)
Inventor
Stephen A Sherwin
Robert B Dubridge
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE194494T1 publication Critical patent/ATE194494T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92922624T 1991-10-21 1992-10-14 Kombinierte zelluläre und immunsuppressive therapien ATE194494T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78107591A 1991-10-21 1991-10-21
PCT/US1992/008969 WO1993007887A1 (en) 1991-10-21 1992-10-14 Combined cellular and immunosuppressive therapies

Publications (1)

Publication Number Publication Date
ATE194494T1 true ATE194494T1 (de) 2000-07-15

Family

ID=25121603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922624T ATE194494T1 (de) 1991-10-21 1992-10-14 Kombinierte zelluläre und immunsuppressive therapien

Country Status (11)

Country Link
US (1) US5670148A (de)
EP (1) EP0610345B1 (de)
JP (1) JPH07500343A (de)
AT (1) ATE194494T1 (de)
AU (1) AU2883192A (de)
CA (1) CA2121487A1 (de)
DE (1) DE69231250T2 (de)
DK (1) DK0610345T3 (de)
ES (1) ES2150424T3 (de)
GR (1) GR3034510T3 (de)
WO (1) WO1993007887A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US6063375A (en) * 1996-09-10 2000-05-16 Medical University Of South Carolina Semiallogeneic cell hybrids and related methods for treating cancer
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
ES2218994T3 (es) * 1998-02-02 2004-11-16 The Johns Hopkins University School Of Medicine Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso.
US20060127366A1 (en) * 1999-06-25 2006-06-15 Mitrani Eduardo N Method and device for inducing biological processes by micro-organs
AU2003271042C1 (en) * 1999-06-25 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem In Vitro Micro-Organs and Uses Related Thereto
AU2007229367B2 (en) * 1999-06-25 2011-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem In Vitro Micro-Organs and Uses Related Thereto
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
US8088568B2 (en) 2001-11-05 2012-01-03 Medgentics, Inc. Dermal micro-organs, methods and apparatuses for producing and using the same
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
HRP20120673T1 (hr) 2003-05-01 2012-10-31 Medgenics, Inc. Uporaba dermalnih mikroorgana
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN102886052B (zh) 2006-09-14 2014-07-30 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
CA2802726A1 (en) 2010-06-15 2011-12-22 Medgenics Medical Israel Ltd. Long lasting drug formulations
CA2810838C (en) 2010-09-08 2021-07-06 The Board Of Regents Of The University Of Texas System Somatostatin receptor-based cancer therapy
EP4282419A1 (de) 2012-12-20 2023-11-29 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
EP3439675A4 (de) 2016-04-08 2019-12-18 Purdue Research Foundation Verfahren und zusammensetzungen für car-t-zelltherapie
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769317A (en) * 1983-06-14 1988-09-06 Hefton John M Process for growing human epidermis, product thereof
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5175004A (en) * 1988-12-27 1992-12-29 Matsumura Kenneth N Propagatable, new combinant cells for cellular replacement therapy
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
EP1041142A3 (de) * 1991-07-15 2007-10-24 Oklahoma Medical Research Foundation Universale Spenderzellen

Also Published As

Publication number Publication date
EP0610345A1 (de) 1994-08-17
US5670148A (en) 1997-09-23
AU2883192A (en) 1993-05-21
EP0610345B1 (de) 2000-07-12
DK0610345T3 (da) 2000-10-23
DE69231250D1 (de) 2000-08-17
GR3034510T3 (en) 2000-12-29
ES2150424T3 (es) 2000-12-01
WO1993007887A1 (en) 1993-04-29
CA2121487A1 (en) 1993-04-29
EP0610345A4 (de) 1997-01-15
DE69231250T2 (de) 2001-03-15
JPH07500343A (ja) 1995-01-12

Similar Documents

Publication Publication Date Title
ATE194494T1 (de) Kombinierte zelluläre und immunsuppressive therapien
DE69535999D1 (de) Verfahren und zusammensetzungen für erhöhte tumorzell-immunität in vivo
AU2953895A (en) Multi-stage cascade boosting vaccine
DK66692D0 (da) En mammal cytokin, il-11
ATE198621T1 (de) Herstellung und verwendung von transgenen mäusen mit fehlender expression von cd28
FI964033A0 (fi) Menetelmiä sairauden hoitamiseksi käyttäen Sertoli-soluja ja allografteja tai ksengrafteja
DK2186902T3 (da) Medicinske præparater til behandling af alfa-galactosidase A-mangel
FR2709309B1 (fr) Compositions cellulaires, préparation et utilisations thérapeutiques.
ES2193143T3 (es) Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
DK0668772T3 (da) Specifik immunsystemmodulering
DK0683669T3 (da) Fremgangsmåder og præparater af en polymer (poloxamer) til cellereparation
AR009560A1 (es) Prolongacion de la sobrevida de injertos con porfirinas
DE69110877D1 (de) Idiotypen-impfung gegen b-zell-lymphoma.
DK0914114T3 (da) Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A
WO2023019225A3 (en) Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
NO890046L (no) Disubstituerte pyridiner.
ES2092573T3 (es) Perfeccionado sistema de aportacion de aire de combustion superior para el control de las emisiones de nox.
WO2002017935A3 (en) A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
ATE226087T1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
PT765398E (pt) Populacao de celulas enriquecedoras em progenitores mieloides e linfoides e metodos de as fazer e utilizar
Billingham et al. “Adoptive” immunization of animals against skin isografts and its possible implications
DK0930877T3 (da) D-methionin til formindskelse af toksiciteten af platinholdige antitumorforbindelser
Szuromi Designer dendritic-cell therapy

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee